Target intelligence / Profile preview

Liposomal phospholipid bilayer

Molecular classification
Other
01

Overview

The liposomal phospholipid bilayer is a structural assembly composed primarily of amphiphilic phospholipids arranged in a double-layered (bilayer) configuration, forming the outer shell of liposomes. Each bilayer consists of hydrophilic phosphate head groups facing outward toward aqueous environments and hydrophobic fatty acid tails oriented inward, away from water, creating a hydrophobic core. This structure enables liposomes to encapsulate hydrophilic or hydrophobic drugs, protect them from degradation, and deliver them to target tissues. The bilayer can be composed of natural or synthetic phospholipids, often stabilized by cholesterol or other sterols, and features physical properties (fluidity, permeability) dictated by the lipid composition. The principal function of the liposomal bilayer is as a vehicle or carrier for therapeutic agents rather than acting as a direct pharmacological target, receptor, enzyme, or transporter. As such, the bilayer itself is not generally considered a conventional therapeutic "target" but rather a delivery platform[3][4][5][8]. Notes on correctness: - "Liposomal phospholipid bilayer" refers to a structure, not a molecular target or receptor; it does not itself mediate biological effects as a target, but provides a vehicle for drug delivery[4][5][8]. - For structured drug-target data extraction, this entry is incorrect as a therapeutic target; it should be classified as a formulation vehicle or delivery system, not a receptor, enzyme, transporter, or other typical drug target.

Other names
Liposome bilayerLiposome lipid bilayerPhospholipid liposome bilayerLiposome membrane
02

Mechanism of action

Acts as a vehicle for drug delivery by encapsulating therapeutic agents and facilitating their entry into cells via fusion, endocytosis, or phagocytosis[2][4][5]

03

Biological functions

Selective barrier formationDrug encapsulationCompartmentalizationDrug delivery
04

Disease associations

Other
05

Safety considerations

Immunogenicity (e.g., accelerated blood clearance with repeated administration)stability and leakage of the drugnon-specific tissue uptakepotential toxicity related to surface modifications[4][5]
06

Interacting drugs

Doxorubicin (Doxil)

4 more in the full profile.

Beyond the preview

Go deeper on Liposomal phospholipid bilayer.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liposomal phospholipid bilayer.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call